SOLID TUMORS

This early-phase trial tested an experimental drug called DF6002, either alone or combined with the approved immunotherapy nivolumab (Opdivo), in 170 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find th…

This small pilot study tested a new type of immune cell therapy called anti-ALPP CAR-T cells in 5 people with advanced solid tumors that have a specific marker (ALPP). The goal was to see if the treatment is safe and whether it can shrink tumors. Participants received chemotherap…

This early-phase study tested whether giving activated natural killer (NK) cells, with or without a protein called rhIL15, is safe and feasible for children and young adults with solid tumors that haven't responded to other treatments. Sixteen participants received chemotherapy t…

This early-phase trial tested a new drug called RS-0139 in 16 people with advanced solid tumors that had stopped responding to standard treatments. The drug is designed to target tumors specifically, and the main goals were to find a safe dose and understand how the body processe…

This early-phase trial tested whether adding nilotinib (a pill) to paclitaxel (a chemotherapy) is safe and tolerable for people with advanced solid tumors that no longer respond to standard treatments. The study included 47 adults and children aged 12 and older. Researchers aimed…

This phase 1 trial tested the combination of dasatinib (a pill) and bevacizumab (an infusion) in 50 adults with advanced solid tumors that no longer respond to standard treatments. The goal was to find the safest dose and see how well the two drugs work together to slow cancer gr…

This study tested an experimental drug called IDX-1197 in 108 adults with solid tumors that have a specific gene change (HRR mutation) and who had no other good treatment options. The goal was to find the safest dose and see if the drug could shrink tumors. The trial was complete…

This early-stage trial tested a combination of immune cells in 9 people with stage IV solid tumors that had stopped responding to standard treatments. The main goal was to see if the therapy is safe and to check for any signs that it might control the disease. The study is now co…

This early-phase trial tested an experimental drug called NEV801 in 78 adults with advanced solid tumors that had stopped responding to standard treatments. The drug was given by IV in increasing doses to find the safest dose and to see if it had any anti-cancer effects. The stud…

This early-phase study tested a new drug called CFT1946 in 89 adults with advanced solid tumors that have a specific BRAF V600 gene mutation. The goal was to find safe doses and see if the drug shrinks tumors when used alone or with other medicines. Participants had already tried…

This early-stage study tested the drug revumenib in 42 adults with colorectal cancer or other solid tumors that had spread or come back after at least one prior treatment. The goal was to see if the drug is safe and can slow tumor growth. Researchers measured side effects, how th…

This early-phase study tested an experimental drug (MK-1454) injected directly into tumors, either alone or with pembrolizumab (Keytruda), in 156 people with advanced solid tumors or lymphomas. The main goals were to find the safest dose and check for side effects. The study also…

This early-phase trial tested a new drug called TdCyd in 27 adults with advanced solid tumors that had stopped responding to standard treatments. The drug is designed to turn back on genes that may slow tumor growth. The main goal was to find a safe dose and check for side effect…

This study tested a drug called bemarituzumab in 260 adults with solid tumors that have high levels of a protein called FGFR2b. The main goals were to see if the drug is safe and if it can shrink tumors. Participants had already tried other treatments without success.

This study tested a new drug called FF-10502-01 in 106 adults with advanced solid tumors or lymphomas that had stopped responding to standard treatments. The goal was to find the safest dose and see if the drug could shrink tumors or slow disease progression. While not a cure, th…

This study looked at whether taking statins (cholesterol-lowering drugs) can reduce hearing loss caused by platinum-based chemotherapy in people with solid tumors. 56 adults who were about to start chemotherapy took part. The goal was to see if statins could protect their ears fr…

This study looked at medical records of 938 adults with solid tumors to see how cancers that spread to different organs—like the liver, brain, lung, or bone—respond to immunotherapy. The goal is to understand why some metastatic sites respond better than others and to help doctor…

This study watched 225 people with solid tumors who got a drug called G-CSF during chemotherapy. G-CSF can cause bone pain. Researchers measured pain levels and tracked what treatments (like pain relievers or other methods) helped. They also checked quality of life, fatigue, mood…

This study in France looked at how satisfied cancer patients were when they switched from getting immunotherapy at the hospital to getting it at home. It included 49 adults with solid tumors. The goal was to see if home treatment improved their care experience.

This study tested whether iPhones and Apple Watches can reliably collect health data from people with cancer. 49 adults undergoing cancer treatment wore an Apple Watch and used an iPhone for 4 months to track activity, fatigue, and thinking skills. The goal was to see if these de…

This study looked at how the cancer drug belinostat is processed in the body by people with advanced solid tumors or blood cancers. Researchers wanted to see if a person's genetic makeup (specifically the UGT1A1 gene) changes how the drug works or causes side effects. The study i…

This study tested tumor tissue from 470 people with solid tumors to look for specific biomarkers. The goal was to see if those biomarkers could help match participants to other Roche clinical trials testing new cancer treatments. The study did not provide treatment itself, but ai…

This study looked at how a new cancer drug (BI 907828) interacts with two other medicines: rifampicin (an antibiotic) and itraconazole (an antifungal). Thirty-three adults with advanced solid tumors who had no other treatment options took BI 907828 alone and then with one of the …

This study tested whether machine learning can analyze facial expressions and voice recordings to measure pain in people with cancer. 83 participants, aged 12 and older, recorded short videos at clinic visits and at home over about 3 months. The goal was to see if this technology…